Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMaria Themeli, Michel Sadelain, Christopher C. Kloss
Estimating the term…
The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.
A population of T cells that are produced by in vitro differentiation of a pluripotent stem cell, wherein (i) the pluripotent stem cell expresses a chimeric antigen receptor (CAR), and (ii) the population of T cells comprises a T cell exhibiting a CD45RA+CD27−CD28−CCR7−CD62L− phenotype.
A method of reducing tumor burden in a subject, comprising administering a population of T cells generated from a pluripotent stem cell that expresses a chimeric antigen receptor (CAR) to said subject having tumor, wherein the population of T cells comprises a T cell exhibiting a CD45RA+CD27−CD28−CCR7−CD62L− phenotype.
A method of increasing survival of a subject having neoplasia, comprising administering a population of T cells generated from a pluripotent stem cell that expresses a chimeric antigen receptor (CAR) to said subject diagnosed with neoplasia, wherein the population of T cells comprises a T cell exhibiting a CD45RA+CD27−CD28−CCR7−CD62L− phenotype.
Dependencies are inferred from the claim text.